Source link : https://www.newshealth.biz/health-news/new-biologic-tulisokibart-beats-placebo-in-uc-trial/
The experimental monoclonal antibody tulisokibart safely induced clinical remission in a phase 2 randomized trial of moderately to severely active ulcerative colitis (UC). In one cohort of 135 patients, the primary endpoint of clinical remission occurred in 26% of those given the novel antibody to tumor necrosis factor–like cytokine 1A (TL1A) vs 1% given placebo […]
Author : News Health
Publish date : 2024-10-02 12:17:34
Copyright for syndicated content belongs to the linked Source.